Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 6/20 | 0.84 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.61 |
| ▸ | HTR7 | P34969 | 2/20 | 0.58 |
| ▸ | DRD2 | P14416 | 2/20 | 0.57 |
| ▸ | HRH1 | P35367 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14218788 | 0.91 | KCNH2 (0.77) | KCNH2ADRB1HTR7DRD2 | |
| SCHEMBL4519876 | 0.91 | KCNH2 (1.00) | KCNH2HTR7 | |
| SCHEMBL13711969 | 0.91 | KCNH2 (0.70) | KCNH2HTR7 | |
| SCHEMBL12879718 | 0.90 | KCNH2 (0.74) | KCNH2ADRB1HTR7DRD2HRH1 | |
| SCHEMBL13711970 | 0.89 | KCNH2 (0.74) | KCNH2ADRB1HTR7DRD2 | |
| SCHEMBL10373770 | 0.88 | ADRB1 (0.74) | KCNH2ADRB1HTR7 | |
| SCHEMBL11103700 | 0.88 | ADRB1 (0.74) | KCNH2ADRB1HTR7 | |
| SCHEMBL10819408 | 0.87 | KCNH2 (0.71) | KCNH2ADRB1HTR7DRD2 | |
| SCHEMBL30563617 | 0.87 | KCNH2 (0.71) | KCNH2ADRB1HTR7DRD2 | |
| SCHEMBL10990710 | 0.87 | KCNH2 (0.80) | KCNH2HTR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | UNIVERSITA DEGLI STUDI DI SIENA (IT) | 2009-09-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090238761-A1 | Novel Aryl Piperazine Derivatives With Medical Utility | HTR2C, HTR2A, DRD2 | KCNH2 769/4885ADRB1 199/4885HTR7 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.